Oncology and Hematology - Global Oncology Academy

Episodes 113-128 of 300

Biomarker Testing in NSCLC: Who, What, When?
Biomarker Testing in NSCLC: Who, What, When?
CME/CE
Biomarker Testing in NSCLC: Who, What, When?
1.00 credit
- Rasheda Persinger MSN, AGNP-C, AOCNP
- Terran Sims, MSN, ACNP-C, CNN, COCN-C
1.00 credit
MinuteCE®
Key NSCLC Data from Singapore and Madrid: Implications to Practice
1.25 credits 5 episodes
- Charu Aggarwal, MD, MPH
- Patrick Forde, M.B.B.Ch.
1.25 credits 5 episodes
Highlights from Singapore on Immunotherapies in Early-Stage NSCLC
Highlights from Singapore on Immunotherapies in Early-Stage NSCLC
MinuteCE®
Highlights from Singapore on Immunotherapies in Early-Stage NSCLC
1.25 program credits
- Charu Aggarwal, MD, MPH
- Patrick Forde, M.B.B.Ch.
1.25 program credits
Highlights from Madrid on Perioperative Immunotherapy in Early-Stage NSCLC
Highlights from Madrid on Perioperative Immunotherapy in Early-Stage NSCLC
MinuteCE®
Highlights from Madrid on Perioperative Immunotherapy in Early-Stage NSCLC
1.25 program credits
- Patrick Forde, M.B.B.Ch.
- Charu Aggarwal, MD, MPH
1.25 program credits
Highlights from Madrid on Targeted Therapy for Advanced NSCLC
Highlights from Madrid on Targeted Therapy for Advanced NSCLC
MinuteCE®
Highlights from Madrid on Targeted Therapy for Advanced NSCLC
1.25 program credits
- Charu Aggarwal, MD, MPH
- Patrick Forde, M.B.B.Ch.
1.25 program credits
Highlights from Singapore on Targeted Therapies in NSCLC
Highlights from Singapore on Targeted Therapies in NSCLC
MinuteCE®
Highlights from Singapore on Targeted Therapies in NSCLC
1.25 program credits
- Charu Aggarwal, MD, MPH
- Patrick Forde, M.B.B.Ch.
1.25 program credits
Highlights from Singapore on Immunotherapies in Metastatic NSCLC
Highlights from Singapore on Immunotherapies in Metastatic NSCLC
MinuteCE®
Highlights from Singapore on Immunotherapies in Metastatic NSCLC
1.25 program credits
- Charu Aggarwal, MD, MPH
- Patrick Forde, M.B.B.Ch.
1.25 program credits
Keeping Up With the Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma
Keeping Up With the Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma
CME/CE
Keeping Up With the Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma
1.00 credit
- Mary Weinstein Dunn
1.00 credit
The Role of PARP Inhibitors in Metastatic Breast Cancer
The Role of PARP Inhibitors in Metastatic Breast Cancer
Project Oncology®
The Role of PARP Inhibitors in Metastatic Breast Cancer
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
Project Oncology®
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
- Jacob Sands, MD
- Jia Luo, MD
Managing AE and Patient Intolerance With Combination Therapy in Early Relapse Multiple Myeloma
Managing AE and Patient Intolerance With Combination Therapy in Early Relapse Multiple Myeloma
MinuteCE®
Managing AE and Patient Intolerance With Combination Therapy in Early Relapse Multiple Myeloma
1.00 program credit
- Joseph Mikhael, MD
1.00 program credit
Carfilzomib-Based Regimens for Early Relapse Multiple Myeloma
Carfilzomib-Based Regimens for Early Relapse Multiple Myeloma
MinuteCE®
Carfilzomib-Based Regimens for Early Relapse Multiple Myeloma
1.00 program credit
- Noa Biran, MD
1.00 program credit
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Upfront ASCT and Lenalidomide Maintenance?
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Upfront ASCT and Lenalidomide Maintenance?
MinuteCE®
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Upfront ASCT and Lenalidomide Maintenance?
1.00 program credit
- Noa Biran, MD
- Joseph Mikhael, MD
1.00 program credit
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
MinuteCE®
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
1.00 program credit
- Noa Biran, MD
- Joseph Mikhael, MD
1.00 program credit
Monoclonal Antibody-Based Regimens for Early Relapse Multiple Myeloma
Monoclonal Antibody-Based Regimens for Early Relapse Multiple Myeloma
MinuteCE®
Monoclonal Antibody-Based Regimens for Early Relapse Multiple Myeloma
1.00 program credit
- Noa Biran, MD
1.00 program credit
MinuteCE®
Early Relapse in Multiple Myeloma: Modern Management Strategies
1.00 credit 10 episodes
- Noa Biran, MD
- Joseph Mikhael, MD
1.00 credit 10 episodes

Previous
1
2
…
6
7
8
9
10
…
18
19
Next

8/11